Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

NCT07625306 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndrome (ACS)

Interventions

DRUG: Pelacarsen
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals